XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues:        
Revenues $ 4,000 $ 373,000 $ 33,000 $ 373,000
Operating expenses:        
Research and development 2,023,000 4,727,000 4,825,000 10,401,000
General and administrative 1,625,000 1,575,000 3,207,000 3,220,000
Total operating expenses 3,648,000 6,302,000 8,032,000 13,621,000
Operating loss (3,644,000) (5,929,000) (7,999,000) (13,248,000)
Other (expense) income:        
Foreign exchange gains (losses) 3,000 (76,000) 4,000 (161,000)
Interest (expense) income (28,000) 77,000 (26,000) 193,000
Other income (expense), net   (106,000) 52,000 58,000
Total other (expense) income, net (25,000) (105,000) 30,000 90,000
Loss before taxes (3,669,000) (6,034,000) (7,969,000) (13,158,000)
Income tax benefit 412,000 586,000 1,766,000 1,906,000
Net loss (3,257,000) (5,448,000) (6,203,000) (11,252,000)
Dividend on convertible exchangeable preferred shares   (50,000)   (101,000)
Net loss applicable to common shareholders $ (3,257,000) $ (5,498,000) $ (6,203,000) $ (11,353,000)
Redeemable common shareholders        
Basic and diluted earnings per common share:        
Net loss per share - basic   $ (6.57)   $ (13.57)
Net loss per share - diluted $ 0.00 (6.57) $ 0.00 (13.57)
Common Stock        
Basic and diluted earnings per common share:        
Net loss per share - basic (0.72) (6.57) (2.13) (13.57)
Net loss per share - diluted $ (0.72) $ (6.57) $ (2.13) $ (13.57)
Clinical trial supply        
Revenues:        
Revenues $ 4,000 $ 373,000 $ 33,000 $ 373,000